drugset
drugset / Trial / NCT03727451

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451 ↗

Phase 2 Completed 17 enrolled Bellerophon
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term extension study

Timeline

Start
2019-01-30
Primary completion
2021-09-07
Completion
2022-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject iNO Unknown 30 ug/kg Inhaled
Subject iNO Unknown 45 ug/kg Inhaled
Subject iNO Unknown 75 ug/kg Inhaled
Subject iNO Unknown 125 ug/kg Inhaled

Indications

pulmonary fibrosis pulmonary hypertension pulmonary sarcoidosis